The Impact of Targetable Mutations on Clinical Outcomes of Metastatic Epidural Spinal Cord Compression in Patients With Non–Small-Cell Lung Cancer Treated With Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy)

This study focuses on patients with non-small cell lung cancer (NSCLC) that has spread to the spine, causing compression of the spinal cord. These patients were treated using a combination of surgery and stereotactic body radiation therapy (SBRT). This combined approach is called hybrid therapy. The research aims to understand how well this hybrid therapy works in these patients and to see if certain genetic mutations in the cancer cells affect the treatment outcome. Specifically, the study looks at the presence of EGFR mutations and their impact on survival. The findings suggest that hybrid therapy is effective for local tumor control. Also, patients who had not previously received EGFR-targeted therapy and started it after the hybrid therapy showed better survival rates. The presence of a specific EGFR mutation (exon 21) was also linked to improved progression-free survival.

• 1
  Hybrid therapy (surgery followed by SBRT) resulted in a 95% local control rate at 2 years after surgery in patients with NSCLC and metastatic epidural spinal cord compression (MESCC).
• 2
  EGFR treatment–naïve patients who initiated EGFR-targeted therapy after hybrid therapy had significantly improved overall survival compared to those who had received EGFR-targeted therapy before hybrid therapy.
• 3
  The presence of EGFR exon 21 mutation was predictive of improved progression-free survival in patients treated with hybrid therapy.